Market confidence is improving across several key assets, but the outlook is still mixed. Copper is benefiting from stronger risk appetite, long-term demand from electrification, and supply concerns, while Pfizer is showing signs of recovery as its non-COVID business grows. At the same time, AUD/USD is gaining support from Australia's higher interest-rate outlook and a softer US dollar.
Still, caution is needed. High copper inventories, falling COVID-related sales at Pfizer, patent competition, and global uncertainty could all limit further upside. Overall, the market tone is more positive than before, but the next move will depend on demand, inflation, interest rates, and broader confidence.
Copper Climbs as Market Confidence Returns
Copper is trading near $6.19 per pound, its strongest level since January 2026. Prices have risen about 10.4% in the past four weeks and around 33% over the past year.
The recent move higher has been supported by hopes of a possible U.S.-Iran peace deal, which improved market confidence. Investors are also still treating copper as an important metal because it is widely used in construction, power grids, electric vehicles, and technology.
However, the market is not completely one-sided. Some inventory data suggests there is still enough copper available in storage, which could limit further gains if demand slows.
Copper Demand Strong, but Caution Builds
Copper prices are being supported by strong long-term demand. The metal is used in power lines, electric vehicles, data centers, buildings, and many new technologies, so investors expect demand to stay high in the years ahead.
Supply worries are also helping prices. Problems at some copper mines and tight availability of raw copper material have made traders concerned that future supply may not be enough.
Still, there are reasons to be cautious. Copper stocks in warehouses remain fairly high, which means the market is not facing an immediate shortage. China is another concern, as its copper imports fell sharply earlier this year, suggesting that high prices may be making buyers more careful.
Rates, Inflation, and the Dollar Shape Copper's Path
Copper is affected by interest rates because it is closely linked to construction, manufacturing, and business investment. When rates stay high, borrowing becomes more expensive, which can slow activity in these areas and reduce demand for copper.
The Federal Reserve recently kept interest rates unchanged, and markets now expect rates to remain high for longer. That makes investors more cautious about industrial metals like copper.
Inflation worries are also important. Recent geopolitical tensions have raised concerns about higher energy and transport costs, which could keep inflation sticky and delay rate cuts.
On the positive side, a weaker US dollar can support copper prices. Since copper is priced in dollars, it becomes cheaper for buyers using other currencies when the dollar falls.
Copper Stays Strong, but Risks Remain
Copper still has a strong long-term story, especially because it is needed for power grids, electric vehicles, data centers, and clean energy projects.
The positive case is that global tensions ease, China's demand improves, and investors continue buying copper when prices dip.
The neutral case is that prices move sideways for a while. Strong future demand may support the market, but high warehouse stocks and softer buying from China could limit gains.
The negative case is that copper pulls back if demand stays weak, inventories remain high, or US interest-rate expectations become less supportive.
Pfizer's Global Medicine Machine
Pfizer is one of the world's largest pharmaceutical companies. It develops and sells medicines and vaccines used to treat or prevent many health conditions.
The company works in areas such as cancer care, heart and metabolic health, vaccines, and immune-related diseases. In 2025, Pfizer made $62.58 billion in revenue.
Pfizer's large product base gives it global reach and steady demand across many markets. However, like most drug companies, it must keep developing new medicines as older products face competition or lower sales over time.
Pfizer Starts 2026 on a Stronger Note
Pfizer Inc. announced its first-quarter 2026 results on Tuesday, May 5, 2026. The company made $14.45 billion in revenue, which was 5% higher than the same period last year. In simple terms, Pfizer sold more medicines and vaccines than it did a year earlier.
Pfizer earned $0.47 per share under standard accounting rules, while its adjusted earnings were $0.75 per share. Adjusted earnings remove some one-off costs and are often used by investors to judge the company's core performance.
As of May 7, 2026, Pfizer's share price was around $26.43. The company also kept its full-year 2026 forecast unchanged, expecting $59.5 billion to $62.5 billion in revenue and adjusted earnings of $2.80 to $3.00 per share.
Pfizer's Growth Beyond COVID
Pfizer's biggest positive sign is that its business outside COVID products is growing. In the first quarter, revenue excluding Comirnaty and Paxlovid increased by 7%. This means Pfizer is becoming less dependent on its COVID vaccine and COVID treatment.
Newer and recently acquired medicines are also helping the company. Sales from these products rose by 22%, showing that Pfizer's newer drug portfolio is gaining traction.
Several medicines performed well. Padcev grew 39%, oncology biosimilars grew 52%, Nurtec/Vydura grew 41%, and Lorbrena grew 32%. This is important because Pfizer needs these newer products to make up for falling COVID-related sales.
COVID Sales Fade, Competition Rises
Pfizer's biggest challenge is that sales from its COVID products are still falling quickly. Comirnaty, its COVID vaccine, dropped 59%, while Paxlovid, its COVID treatment, dropped 63%.
This is happening because fewer people are getting COVID shots, infection levels are lower, and governments are buying fewer COVID-related products than before.
Pfizer also faces competition from cheaper versions of some medicines. When patents expire, other companies can sell generic or biosimilar alternatives. Pfizer expects this to reduce 2026 revenue by about $1.5 billion.
AUD/USD Climbs as RBA Surprise Fuels Aussie Strength
AUD/USD is trading around 0.7243 on May 7, 2026, close to a recent high. The Australian dollar has gained about 2.8% over the past month and roughly 13% over the past year.
The tone is mildly bullish, mainly because the RBA surprised markets with another rate hike on May 5, 2026, while the Fed kept rates unchanged.
This means AUD/USD is moving higher because Australia's interest-rate outlook currently looks more supportive than the US outlook.
RBA Hike Gives the Aussie a Yield Advantage
The RBA raised the cash rate by 25 basis points to 4.35% on May 5, 2026, saying inflation is likely to stay above target, and upside risks remain.
The Fed, by contrast, kept rates unchanged at 3.50%–3.75% on April 29, 2026, while pointing to solid economic activity, elevated inflation, and uncertainty linked to the Middle East.
This rate gap now favors the Australian dollar because investors can earn relatively more yield from holding AUD than USD.
Australia's inflation outlook is still uncomfortable, with the RBA forecasting headline inflation to peak at 4.8% in Q2 2026 and trimmed mean inflation to stay above 3% until mid-2027.
Market Mood Turns Bullish on the Aussie
The market is already showing a more positive view on the Australian dollar, with sentiment improving as AUD/USD trades near recent highs.
This shows that the market has moved from last year's bearish stance on the Aussie into a clear long position. That supports upward momentum, but it also increases the risk of profit-taking if sentiment turns.
Broader risk appetite is also helping AUD/USD, as the US dollar has recently softened while commodity-linked currencies have benefited from stronger demand.
AUD/USD Outlook Stays Positive but Cautious
The short-term outlook for AUD/USD is slightly positive, but there are still risks.
The pair could move higher if investors expect more RBA rate hikes, if iron ore prices remain strong, or if the US dollar continues to weaken.
The main risks are weaker demand from China, a stronger US dollar, or rising tensions in the Middle East that hurt confidence in global markets.
Overall, AUD/USD looks supported above 0.7100, but further gains may become harder if too many investors are already positioned for the Australian dollar to rise.
This material is provided for informational purposes only and does not constitute investment advice or a recommendation to trade. Financial markets involve risk, and past performance is not indicative of future results.
